Codebase

Arbor Biotechnologies Announces Collaboration with Ginkgo Bioworks to Advance the Discovery and Development of Precision Gene Editors

Retrieved on: 
Tuesday, December 12, 2023
NYSE, DNA, Gene editing, Protein engineering, Genome, Ginkgo Bioworks, CRISPR, PAMS, Ginkgo, Patient, Codebase, Foundry, Vaccine, Pharmaceutical industry, Arbor

Arbor utilizes its computational metagenomic discovery engine and protein engineering expertise to identify and optimize genetic editors with the potential to treat a broad range of genetic diseases.

Key Points: 
  • Arbor utilizes its computational metagenomic discovery engine and protein engineering expertise to identify and optimize genetic editors with the potential to treat a broad range of genetic diseases.
  • "Ginkgo's expertise aligns well with our goals, and their technology will synergize with our in-house capabilities, potentially fueling a faster, more efficient expansion of our toolbox of gene editing technologies."
  • "This collaboration with Arbor is an exciting project for us, as it gives us an opportunity to leverage our platform-driven approach to contribute to the gene editing sector's fast-moving evolution.
  • We look forward to expanding our capabilities in this field by working with such an innovative pioneer as Arbor to power technologies with the potential for transformative impact."

Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity

Retrieved on: 
Tuesday, August 29, 2023
Cloud, Intelligence, Centers for Disease Control and Prevention, LLM, DNA, Intellectual property, TPU, Partnership, DARPA, Intelligence Advanced Research Projects Activity, Therapy, Codebase, Global Initiative, SARS-CoV-2, Biogen, Enterprise search, Agriculture, Biotechnology, Synthetic media, COVID-19, Concentric objects, Google Cloud Platform, Public, Sumitomo Chemical, Research, Genomics, Synthetic biology, Government, CDC, Cloud computing, BigQuery, Protein, Moscone Center, Collection, Machine learning, Google Cloud, Engineering, Novo Nordisk, Tensor, Stockholm Environment Institute US Center, Foundry, Drug discovery, Biology, Merck, AI, Ecosystem, GISAID, NYSE, IARPA, Mobile phone, Satellite navigation device, Video game, Network equipment provider, Syngenta, Bayer, Ginkgo

Ginkgo intends to make Google Cloud its primary cloud services provider, significantly increasing its next-generation cloud computing resources, positioning Ginkgo and its customers well as the need for cloud computing expands.

Key Points: 
  • Ginkgo intends to make Google Cloud its primary cloud services provider, significantly increasing its next-generation cloud computing resources, positioning Ginkgo and its customers well as the need for cloud computing expands.
  • "We believe that by partnering with Google Cloud, Ginkgo can supercharge our mission to make biology easier to engineer," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks.
  • Ginkgo operates as a horizontal biological engineering and biosecurity platform, working to accelerate and de-risk scientific R&D projects for customers across industries.
  • Ginkgo and Google Cloud anticipate fueling a number of new Ginkgo offerings and initiatives through the collaboration, including:
    Large language models for biological engineering: Ginkgo plans to leverage Google Cloud's Vertex AI platform and Ginkgo's expansive Codebase to build and train novel foundation and task-specific models for core biological engineering challenges, supported by Google Cloud Consulting .

CodeSee Enhances Platform with AI-Powered Code Understanding Feature to Revolutionize Coding Experience

Retrieved on: 
Wednesday, July 19, 2023
Overalls, AI, Intelligence, Walking, Codebase, SAN, Map, Medical device, Sales

SAN FRANCISCO, July 19, 2023 (GLOBE NEWSWIRE) -- CodeSee, the world’s only code visibility platform that helps developers understand, on or offboard, build, and refactor applications, today announced the launch of an artificial intelligence (AI)-powered codebase understanding feature. This brings the power of generative AI to developers to significantly reduce onboarding time for new engineers, improve efficiency in code refactoring, as well as increase productivity coding day-to-day.

Key Points: 
  • Software codebases have become increasingly large and complex, which will only get worse as more code is generated using AI tools.
  • CodeSee is addressing this challenge with the introduction of a new AI feature enabling developers to interrogate their codebases directly, decreasing time spent on code comprehension and increasing overall productivity.
  • The new AI feature provides:
    Intelligent Codebase Understanding: AI-powered code understanding enables developers to query their codebase and receive responses to questions like, “How does authentication work?
  • Efficient Refactoring: The platform provides a detailed map of code connections and flows, providing a solid base for efficient and accurate code refactoring.

Ambrosia Bio Leverages Ginkgo Enzyme Services to Develop a More Scalable Enzymatic Process for Allulose

Retrieved on: 
Thursday, June 29, 2023
Starch, Taste, DNA, Business development, Food, Codebase, Sugar, Business, Temperature, ET, Blood, Ginkgo Bioworks, Ginkgo, Carbohydrate, Sucrose, Molasses, FDA, NYSE, Psicose, Fine chemical, Ambrosia

JERUSALEM and BOSTON, June 29, 2023  /PRNewswire/ -- Ambrosia Bio, an Israeli foodtech company developing novel bioprocesses for the global sugar replacement industry, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ambrosia Bio will leverage Ginkgo Enzyme Services, including its proprietary chassis organisms, to develop an expression strain for the scalable production of the Ambrosia Bio proprietary enzymes used for the conversion of feedstock into allulose.

Key Points: 
  • Mass production of allulose requires enzymatic conversion of common carbohydrates, but many of the natural enzymes available on the market today lack stability and effectiveness.
  • In particular, Ambrosia Bio seeks to benefit from access to Ginkgo's extensive strain engineering Codebase, as well as Ginkgo's Foundry capabilities in enzyme expression and analytical chemistry, to develop a more scalable and affordable commercial allulose solution.
  • "Ginkgo has established itself as a global leader in the synthetic biology ecosystem and precision fermentation space," said Ziv Zwighaft, Founder and CEO at Ambrosia Bio.
  • "With end-to-end capabilities, Ginkgo is a one-stop shop that can enable Ambrosia Bio to expand global allulose availability.

Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat Diseases

Retrieved on: 
Monday, May 8, 2023
Metagenomics, Drug discovery, Boehringer Ingelheim, Database, DNA, Partnership, Acquisition, Ginkgo Bioworks, Ginkgo, NYSE, Disease, Patient, Pharmaceutical industry, Fine chemical, Zymergen, Codebase

BOSTON, May 8, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership with Boehringer Ingelheim.

Key Points: 
  • BOSTON, May 8, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership with Boehringer Ingelheim.
  • Hundreds of millions of people are living with diseases that to date cannot be cured or are inadequately treated.
  • "Ginkgo is well-positioned to help partners like Boehringer Ingelheim complement their drug discovery efforts particularly when it comes to natural product discovery," said Jason Kelly, CEO and co-founder at Ginkgo Bioworks.
  • "We are thrilled to work with Boehringer Ingelheim leveraging our Foundry and Codebase to unlock new possibilities in biopharma innovation."

Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform

Retrieved on: 
Thursday, February 9, 2023
Biotechnology, Pharmaceutical, Health, Oncology, MBA, Synthetic biology, Francis Crick Institute, Immunotherapy, Ginkgo Bioworks, Cancer, Vanderbilt-Ingram Cancer Center, Principal Group, Doctor of Pharmacy, RNA, Bladder cancer, Codebase, Salmonella, Partnership, Bacillus, Albright, BCG, Doctor of Philosophy, MD, Vaccine

Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has raised $30 million in new funding.

Key Points: 
  • Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has raised $30 million in new funding.
  • This follows Prokarium’s announcement of partnering with Ginkgo Bioworks to leverage its world-class Foundry and extensive Codebase to develop a bactofection platform technology.
  • “We are excited to advance our vision to create living cures,” said Kristen Albright, PharmD, Chief Executive Officer of Prokarium.
  • “Proceeds of this financing will fund our lead oncology program entering clinical development this year and enable platform expansion for the delivery of novel therapeutic payloads, including RNA, via our proprietary bacteria.

Ginkgo Bioworks Expands Its R&D Facilities, Opens Bioworks7 to Conduct Mammalian Screening at Scale, Widening Capabilities for Biopharma Partners

Retrieved on: 
Friday, January 6, 2023
IPSC, Merck, Heel, DNA, Ginkgo, CAR, Ginkgo Bioworks, Growth, Biosafety, NYSE, Persephone, Novo Nordisk, Biogen, Therapy, Engineering, Robotics, RNA, Cell, Fine chemical, AbbVie, Codebase, Seaport District, Plasmodium circularis

BOSTON, Jan. 6, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the opening of Bioworks7, the latest expansion of its biological engineering foundry. With this new space, Ginkgo increases its capacity and capabilities to serve its partners in the spaces of cell and gene therapy, biomanufacturing and general mammalian programming for therapeutic applications and new biopharmaceutical modalities.

Key Points: 
  • Ginkgo's foundry automates and scales the process of organism engineering, allowing engineers to prototype thousands of biological designs.
  • "With Bioworks7, Ginkgo is able to further scale this work with dedicated capabilities for stem cell engineering, centralized mammalian cell operations services and expanded capabilities in existing areas."
  • Today's launch will provide Ginkgo with the capacity to interface with more strategic partners to advance improved cells into therapeutics or biomanufacturing.
  • As its platform evolves to spearhead monumental work in the biopharma space, Ginkgo is equipping companies with the tools they need to innovate and shape therapeutics.

United Kingdom NFT Market Intelligence Report 2022-2028 - NFT Marketplaces are Raising Funding Rounds to Drive their Growth

Retrieved on: 
Thursday, December 29, 2022
Spend, Ecosystem, Blockchain, Netflix, Social media, Investment, NFT, Growth, Venture capital, Codebase, Non-fungible token, Government, Sale, Adobe, GBV, Renewable energy, Cryptocurrency, Video game, United, Adidas, Metaverse

The non-fungible tokens (NFT) market has recorded significant growth over the last 12 months globally, and the trends are similar in the United Kingdom.

Key Points: 
  • The non-fungible tokens (NFT) market has recorded significant growth over the last 12 months globally, and the trends are similar in the United Kingdom.
  • This trend is expected to accelerate as innovative startups with strong business models continue to enter the United Kingdom NFT industry.
  • In the growing prominence and popularity of the NFT market in the United Kingdom, NFT startups are raising funding rounds to further accelerate the growth of their marketplaces.
  • United Kingdom NFT Market Size and Future Growth Dynamics by Key Performance Indicators, 2019-2028
    United Kingdom NFT Market Size and Forecast by Key Assets, 2019-2028

United Kingdom NFT Market Intelligence and Future Growth Report 2022: Market is Expected to Grow by 48.7% to Reach $1725.2 Million in 2022 - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 5, 2022
Professional Services, NFT, Spend, Blockchain, Social media, Ecosystem, Netflix, Sale, NFT, Codebase, Non-fungible token, GBV, Government, Investment, Adobe, Growth, Venture capital, Cryptocurrency, Renewable energy, Video game, Metaverse, Adidas, United

NFT industry in United Kingdom is expected to grow by 48.7% on an annual basis to reach US$1725.2 million in 2022.

Key Points: 
  • NFT industry in United Kingdom is expected to grow by 48.7% on an annual basis to reach US$1725.2 million in 2022.
  • The NFT Spend Value in the country will increase from US$1725.2 million in 2022 to reach US$9257.0 million by 2028.
  • This trend is expected to accelerate as innovative startups with strong business models continue to enter the United Kingdom NFT industry.
  • United Kingdom NFT Market Size and Future Growth Dynamics by Key Performance Indicators, 2019-2028
    United Kingdom NFT Market Size and Forecast by Key Assets, 2019-2028

Bolt Threads Announces Latest Collaboration with Ginkgo Bioworks to Optimize its Mylo™ Material

Retrieved on: 
Thursday, October 20, 2022
U.S. Securities and Exchange Commission, Color, Hypergymnasia, K-12, Computer, SEC, Therapy, Risk, Efficiency, Agriculture, COVID-19 testing, NYSE, Biotechnology, Synthetic biology, Fungus, Program, Entrepreneurship, Partnership, Technology, Textile, Mycelium, Acquisition, Industry, Bolt, CEO, Soarin' Eagle, Protein, Food, Forward-looking statement, DNA, Fast Company, Adidas, COVID-19, Solution, Livestock, Fur clothing, Risk management, Kering, Ginkgo, Codebase

BOSTON, Oct. 20, 2022 /PRNewswire/ -- Bolt Threads, a biotechnology company creating the next generation of advanced materials, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a multi-project collaboration to increase the production efficiency and performance of Bolt's current portfolio as well as expand it by developing novel proteins for biomaterials. The first program in this collaboration aims to optimize the production efficiency of Bolt's Mylo™ material, a leather alternative made out of mycelium, the underground root-like system of fungi.

Key Points: 
  • The first program in this collaboration aims to optimize the production efficiency of Bolt's Mylo material, a leather alternative made out of mycelium, the underground root-like system of fungi.
  • Through this collaboration, Ginkgo aims to increase the growth rate of Bolt's mycelium, lowering the overall production costs of Mylo.
  • This collaboration also marks an expansion of the companies' work together, as they are already working to optimize the sustainability, efficiency and cost effectiveness of Bolt Threads' b-silkprotein manufacturing process.
  • Bolt Threads is at the forefront of this shift, and Mylo represents this future," said Jason Kelly, CEO and co-founder, Ginkgo Bioworks.